IRIDEX Corporation — FY2014 Form 10-K
Business context and reporting period. IRIDEX develops and sells ophthalmic laser systems, delivery devices, consumables, and related services for sight-threatening eye diseases. The filing covers the fiscal year ended January 3, 2015; FY2014 included 53 weeks, versus 52 weeks in FY2013. The aesthetics business, sold in 2012, is reported as discontinued operations; FY2014 results are from continuing ophthalmology operations.
Financial performance and liquidity
| Metric | FY2014 | FY2013 |
|---|---|---|
| Revenue | $42.8 million | $38.3 million |
| Gross profit / gross margin | $21.4 million / 50.0% | $18.6 million / 48.6% |
| Operating income | $2.6 million | $2.6 million |
| Income before taxes | $1.3 million | $2.3 million |
| Net income | $10.0 million | $2.2 million |
| Diluted EPS | $0.97 | $0.22 |
| Cash from operating activities | $4.0 million | $0.8 million |
- Revenue increased 11.9%. Systems revenue rose to $23.5 million from $19.3 million; recurring revenue was $19.3 million, up 3.4%. International sales were $20.2 million, or 47.2% of revenue.
- Gross margin improved 1.4 percentage points, reflecting direct-margin improvement and production overhead efficiencies, partly offset by manufacturing variances and a lower recurring-revenue share of sales.
- Net income included an $8.7 million income-tax benefit, principally from releasing $9.2 million of valuation allowance on deferred tax assets. Pre-tax income declined year over year, and the tax benefit was the main driver of the increase in reported net income.
- Cash and cash equivalents were $13.3 million at year-end, working capital was $25.9 million, and the company reported no debt. Total assets were $41.8 million and total liabilities were $8.1 million.
- FY2014 cash use included $4.7 million of share repurchases and $0.6 million of capital expenditures; stock-option exercises generated $1.5 million. Management stated that cash and expected operating cash flows should fund operations for at least the next 12 months.
Material changes versus FY2013
- Domestic and international systems revenue grew 18.9% and 24.1%, respectively, supported by IQ MicroPulse laser sales and the TxCell scanning delivery device.
- Recurring revenue growth was attributed partly to the first full year of sales under the Peregrine agreement and higher GreenTip sales through Alcon. OEM revenue fell to zero as Bausch & Lomb discontinued the product.
- R&D expense rose 25.7% to $4.6 million, including investment in the Cyclo G6 system and IQ platform cost-reduction programs. Sales and marketing expense rose 5.6%; general and administrative expense rose 20.1%.
- Interest and other expense increased to $1.3 million, primarily because of a $1.3 million increase in the fair value of acquisition-related earn-out liabilities, reflecting higher expected future revenues.
Outlook, risks, contingencies, and unusual items
- Management described the outlook for systems sales as positive, citing wider adoption of MicroPulse therapy. The filing provides no numerical revenue or earnings guidance.
- Key risks include intense competition from laser-device makers and pharmaceutical treatments; reliance on international distributors for nearly half of sales; reimbursement uncertainty; product development, clinical evidence, and regulatory-clearance risks; and dependence on sole- or limited-source suppliers.
- International sales are denominated in U.S. dollars, so dollar appreciation could make products less competitive abroad. The company did not hedge currency exposure.
- Contractual obligations totaled $10.9 million: $2.0 million for operating leases and $8.9 million for supplier and contract-manufacturer commitments. The Peregrine agreement included a $750,000 annual minimum purchase commitment; FY2014 purchases were $678,000, with the $72,000 shortfall added to the FY2015 commitment.
- Management reported no material pending legal proceedings and no off-balance-sheet arrangements. The independent auditor issued an unqualified opinion on the financial statements; it did not attest to internal control over financial reporting.
Most important facts for investors to verify
- Whether operating performance and cash generation support the realization of deferred tax assets, which materially boosted FY2014 earnings.
- Whether MicroPulse system adoption and recurring consumables, service, and partner sales can sustain growth after OEM revenue ended.
- How the $1.4 million Level 3 earn-out liability changes as projected royalties and acquisition-related revenues develop.
- Whether distributor performance, reimbursement conditions, and foreign-exchange movements affect the nearly 47% international revenue contribution.
- Whether supplier commitments, including the Peregrine minimum, are aligned with demand and inventory needs.